Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Porton Biologics Raises $61 Million for Cell/Gene Therapy CDMO Services

publication date: Apr 19, 2021

Suzhou Porton Biologics, a gene and cell therapy CDMO service company, closed a $61 million Series A funding. In late 2020, the Phase I part of Porton's GMP facility was approved, and it began offering services that range from process development to clinical production of plasmids, viral vectors and cell therapies. Proceeds from the financing will support Phase II construction. Porton Biologics is a subsidiary of Chongqing-headquartered CDMO Porton Pharma Solutions. More details....

Stock Symbol: (SHA: 300363)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021